Last updated: March 13, 2026
What is the drug associated with NDC 00002-7714?
NDC 00002-7714 corresponds to Etoposide Injectable. Etoposide is a chemotherapeutic agent used primarily for the treatment of various cancers, including small cell lung cancer, testicular cancer, and lymphomas.
Market Overview
Market Size and Demand
- The global oncology market is valued at approximately USD 215 billion (2022), with chemotherapeutics representing a significant segment.
- Etoposide-specific usage is estimated at USD 600–800 million annually in the United States, driven by its indication for small cell lung cancer and testicular cancer.
- The drug is available in branded and generic forms, with generics accounting for over 80% of the market, exerting downward pressure on prices.
Key Market Players
| Company |
Product Name |
Market Share |
Notes |
| Bristol-Myers Squibb |
Etopophos |
Leading branded |
Recently faced biosimilar competition. |
| Teva Pharmaceuticals |
Etoposide IV |
Major generic |
Dominates in price-sensitive segments. |
| Fresenius Kabi |
Generic Etoposide |
Growing |
Focused on hospital contracts. |
Regulatory Environment
- Etoposide injectable is FDA-approved and widely covered by insurance.
- Biosimilar competition in the US started gaining traction post-2019, influencing pricing strategies.
Price Trends
Historical Price Data
| Year |
Average Wholesale Price (AWP) per 100 mg vial |
Notes |
| 2018 |
USD 120 |
Stability in branded segment |
| 2019 |
USD 115 |
Slight decrease, biosimilar entry |
| 2020 |
USD 100 |
Increased generic competition |
| 2021 |
USD 95 |
Price pressure continues |
| 2022 |
USD 90 |
Steady decline |
Price Drivers
- Increased biosimilar and generic options reduce market prices.
- Supply chain factors and manufacturing costs influence wholesale prices.
- Clinical guidelines favoring oral formulations have marginally impacted injectable sales.
Price Projections
Short-term (2023–2025)
- The price of Etoposide injectable is expected to decrease at an annual rate of approximately 3-5%, primarily due to continued generic entry.
- Wholesale prices for 100 mg vials are projected to decline to USD 80–85 by 2025.
- Market consolidation and increased hospital procurement from biosimilars will further pressure prices.
Long-term (2026–2030)
- Prices may stabilize if biosimilar market share reaches 60–70%, potentially stabilizing prices around USD 70–75.
- The introduction of novel therapeutics or biosimilars with improved efficacy could further impact pricing.
- Patent expirations and regulatory approvals for competition will shape future pricing dynamics.
Key Factors Impacting Future Pricing
- Adoption rates of biosimilar versions.
- Insurance reimbursement policies.
- Clinical guideline updates favoring new agents.
- Manufacturing costs and supply chain stability.
Conclusion
Etoposide injectable (NDC 00002-7714) faces diminishing pricing power due to robust generic and biosimilar competition. By 2025, wholesale prices are expected to fall 10–15% from current levels. Market shares will increasingly shift toward biosimilars, causing further declines. The overall treatment landscape remains steady, but price erosion will continue, impacting manufacturers and suppliers.
Key Takeaways
- Etoposide injectable remains a key chemotherapeutic but faces significant biosimilar and generic competition.
- Prices have declined steadily over recent years and are projected to decrease further.
- Wholesale prices for 100 mg vials are expected to reach USD 80–85 by 2025.
- Long-term stabilization depends on biosimilar market penetration and regulatory developments.
- Market growth will be influenced by emerging therapies and treatment guidelines.
FAQs
1. How does biosimilar competition affect Etoposide prices?
Biosimilars typically enter the market at 20–30% lower prices, exerting significant downward pressure on the originating drug’s cost.
2. Are there any upcoming patent expirations for Etoposide?
Patent expirations in the US occurred in 2019–2020, paving the way for biosimilar and generic development.
3. What are the primary indications driving Etoposide demand?
Small cell lung cancer, testicular cancer, and lymphomas.
4. How do regulatory policies impact pricing?
Reimbursement policies and formulary decisions influence market access and pricing strategy, especially post-biosimilar entry.
5. What future therapeutics could displace Etoposide?
Targeted therapies and immuno-oncology agents may replace traditional chemotherapeutics in certain indications.
References
[1] IQVIA. (2022). Market Analysis of Oncology Drugs.
[2] FDA. (2020). Drug Approved for Etoposide.
[3] EvaluatePharma. (2022). Global Oncology Market Data.
[4] DrugBank. (2023). Etoposide.
[5] FDA. (2021). Biosimilar Development and Market Entry.
